CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Biotechnology offers significant opportunities by advancing healthcare through therapeutic proteins, enhancing agricultural productivity and sustainability, and creating bio-based industrial materials ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class allogeneic CAR-T ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and ...

Advances in genome editing have transformed the development of animal models used to understand human diseases. While transgenic mouse models have broadly ...

Emerging biotechnologies, strategic collaborations, and growing focus on personalized and regenerative medicine are accelerating the next wave of gene therapy innovation.Austin, Nov. 05, 2025 (GLOBE ...

TG Therapeutics (NASDAQ: TGTX) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate TG Therapeutics to ...

The U.S. Cell and Gene Therapy Clinical Trials Market Leads Global Growth with Robust Biotech Activity, Regulatory Support, and Expanding Late-Stage Pipelines.Austin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.